Mouse Anti-CALR Recombinant Antibody (clone FMMU-CRT-10) (CAT#: HPAB-0446-YJ)

Figure 1 Identification and characterization of FMU-CRT 2, 8, 10, 17, 20, and 24 mAbs.

Reactivity of FMU-CRT 2, 8, 10, 17, 20, and 24 with membrane CRT identified by flow cytometric analysis. Jurkat cells were stained with the control mAb (gray histogram) or FMUCRT 2, 8, 10, 17, 20, 24 (solid line), respectively.

Liu, R., Gong, J., Chen, J., Li, Q., Song, C., Zhang, J., ... & Jin, B. (2012). Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunology, Immunotherapy, 61(6), 855-864.

Figure 2 Identification and characterization of FMU-CRT 2, 8, 10, 17, 20, and 24 mAbs.

Western blot analysis showed FMU-CRT 2, 8, 10, 17, 20, and 24 could probe the rCRT molecule, control antibody displayed negative reactivity.

Liu, R., Gong, J., Chen, J., Li, Q., Song, C., Zhang, J., ... & Jin, B. (2012). Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunology, Immunotherapy, 61(6), 855-864.

Figure 3 Establishment of the CLEIA system with FMU-CRT-17 mAb as coating antibody and HRP-conjucted FMU-CRT-8 mAb as detection antibody to detect soluble CRT.

Each of the six mAbs was used as coating antibody or as HRP-labeled detection antibody. The optical density (OD) 450 nm absorbance was detected for each antibody combination using sCRT concentration at 100 ng/ml. Histograms represented means of triplicate determinations (bars show mean with SD).

Liu, R., Gong, J., Chen, J., Li, Q., Song, C., Zhang, J., ... & Jin, B. (2012). Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunology, Immunotherapy, 61(6), 855-864.